HDAC inhibitors in HIV.
Fiona Wightman, Paula Ellenberg, Melissa Churchill...
https://pubmed.ncbi.nlm.nih.gov/22083528/Actively Recruiting
Led by National Institute of Allergy and Infectious Diseases (NIAID) · Updated on 2026-10-16
130
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are studying the latent HIV reservoir, which is the virus hiding in the blood of people living with HIV, even when their infection is under control with antiretroviral therapy ART. This reservoir is a major obstacle to curing HIV. The study focuses on Ugandans with HIV who have suppressed viral loads, aiming to measure the reservoir size and understand factors affecting it. This knowledge may help develop new strategies to prevent or control HIV. The study involves four groups of participants those on ART with suppressed viral loads, those with a known recent infection window, those with suppressed viral loads not on ART, and those who started ART early after infection. Participants will have yearly visits over 20 years, including fingerstick hemoglobin screening and blood draws. Blood samples will be analyzed for viral latency, immune responses, and other markers to track changes in the latent reservoir over time. Participants will undergo medical history reviews, physical exams, and questionnaires about their health. Researchers will monitor viral loads, immune activation, and other factors related to HIV latency. Blood will be tested for other diseases and pregnancy when applicable. The studys long-term follow-up will help understand the decay and formation rates of the latent HIV reservoir in this population, comparing findings to Western cohorts.
CONDITIONS
Quantitative Measurement and Correlates of the Latent HIV Reservoir in Virally Suppressed Ugandans
V
Vivien O Akiror
S
Steven J Reynolds, M.D.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
National Institute of Allergy and Infectious Diseases (NIAID)
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 20 years
Participants have yearly visits for medical history, physical exams, fingerstick hemoglobin tests, and blood draws. Blood samples are analyzed to study the latent HIV reservoir and immune responses over time.
Annual visits
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Fiona Wightman, Paula Ellenberg, Melissa Churchill...
https://pubmed.ncbi.nlm.nih.gov/22083528/Ya-Chi Ho, Liang Shan, Nina N Hosmane...
https://pubmed.ncbi.nlm.nih.gov/24243014/National Institute of Allergy and Infectious Diseases (NIAID)
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborating Sponsor